Treatment of pulmonary embolism by subcutaneous low-molecular-weight heparin in a hemodialysis patient

American Journal of Nephrology

Volumn 18, Issue 4, 1998, Pages 325-328

  Szeto, C C ^a   Wang, Angela Y M ^a   Lui, S F ^a   Lai, K N ^a   Yu, Alex W ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Hemodialysis; Low molecular weight heparin; Pulmonary embolism

Indexed keywords

ANTICOAGULANT AGENT; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; ARTICLE; CASE REPORT; CENTRAL VENOUS CATHETERIZATION; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; HEMODIALYSIS; HUMAN; LUNG EMBOLISM; MALE; PRIORITY JOURNAL;

ADULT; ANTICOAGULANTS; CATHETERIZATION, CENTRAL VENOUS; HUMANS; JUGULAR VEINS; MALE; NADROPARIN; PULMONARY EMBOLISM; RENAL DIALYSIS;

EID: 0031779208     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000013359     Document Type: Article

References (27)

1. Rello J: Pulmonary embolism due to an indwelling venous catheter. Chest 1991;100: 1477-1478.
2. Hoekstra MO, Tamminga RY, Knol K, van Aalderen WM: Pulmonary embolism as a complication of a central venous access catheter. Eur J Pediatr 1994;153:613.
3. Cervia JS, Caputo TA, Davis SD; Murray HW: Septic pulmonary embolism complicating a central venous catheter. Chest 1990;98:1526.
4. Vanholder R, Lameire N, Verbanck J, van Rattinghe R, Kunnen M, Ringoir S: Complications of subclavian catheter hemodialysis: A 5 year prospective study in 257 consecutive patients. Int J Artif Organs 1982;5:297-303.
5. Almirall J, Campistol JM, Rello J, Ponz E, Revert L: Central vein catheters for hemodialysis. Nephron 1989;51:296.
6. Gibson SP, Mosquera D: Five years experience with the Quinton Permcath for vascular access. Nephrol Dial Transplant 1991;6:269-274.
7. Barrit DW, Jordan SC: Anticoagulant drugs in the treatment of pulmonary embolism: a controlled clinical trial. Lancet 1960;1:1309-1312.
8. Hall R: Difficulties in the treatment of acute pulmonary embolism. Thorax 1985;40:729-733.
9. Hyers TM, Hull RD, Weg JG: Antithrombotic therapy for venous thromboembolic disease. Chest 1989;95(suppl):37S-51S.
10. Carson JL, Kelley MA, Duff A, Weg JG, Fulkerson WJ, Palevsky HI, Schwartz JS, Thompson BT, Popovich J Jr, Hobbins TE, Spera MA, Alavi A, Terrin ML: The clinical course of pulmonary embolism. N Engl J Med 1992;326: 1240-1245.
11. Gallus A, Jackaman J, Tillett J, Mills W, Wycherley A: Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet 1986;ii: 1293-1296.
12. Hirsh J: Oral anticoagulant drugs. N Engl J Med 1991;324:1865-1875.
13. Bergqvist D: Review of clinical trials of low molecular weight heparins: Clinical review. Eur J Surg 1992;158:67-78.
14. Lensing AW, Prins MH, Davidson BL, Hirsh J: Treatment of deep venous thrombosis with low-molecular-weight heparins: A meta-analysis. Arch Intern Med 1995;155:601-607.
15. Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, Ginsberg J, Turpie AG, Demers C, Kovacs M, Geerts W, Kassis J, Desjardins L, Cusson J, Cruickshank M, Powers P, Brien W, Haley S, Willan A: A comparison of low-molecular weight heparin administration primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996;334:677-681.
16. Koopman MM, Prandoni P, Piovella F, Ockelford PA, Brandjes DP, van der Meer J, Gallus AS, Simonneau G, Chesterman CH, Prins MH, Bossuyt PM, de Haes H, van den Belt GM, Sagnard L, d'Azemar P, Buller HR: Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular weight heparin administered at home. The Tasman Study Group. N Engl J Med 1996;334: 682-687.
17. Dalen JE, Alpert JS: Natural history of pulmonary embolism. Prog Cardiovasc Dis 1975;17: 257-270.
18. Grau E, Siguenza F, Maduell F, Linares M, Olaso MA, Martinez R, Caridad A: Low molecular weight heparin (CY-216) versus unfractionated heparin in chronic hemodialysis. Nephron 1992;62:13-17.
19. Ljungberg B, Blomback M, Johnsson H, Lins LE: A single dose of a low molecular weight heparin fragment for anticoagulation during hemodialysis. Clin Nephrol 1987;27:31-35.
20. Schrader J, Stibbe W, Armstrong VW, Kandt M, Muche R, Kostering H, Seidel D, Scheler F: Comparison of low molecular weight heparin to standard heparin in hemodialysis/hemofiltration. Kidney Int 1988;33:890-896.
21. Anastassiades E, Ireland H, Flynn A, Lane DA, Curtis JR: A low molecular weight heparin (Kabi 2165, 'Fragmin') in repeated use for hemodialysis: prevention of clotting and prolongation of the venous compression time in comparison with commercial unfractionated heparin. Nephrol Dial Transplant 1990;5:135-140;
22. Thery C, Simonneau G, Meyer G, Helenon O, Bridey F, Armagnac C, d'Azemar P, Coquart JP: Randomized trial of subcutaneous low-molecular-weight heparin CY216 (Fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism: A dose-ranging study. Circulation 1992;85:1380-1389.
23. Caranobe C, Barret A, Gabaig AM, Dupouy D, Sie P, Boneu B: Disappearance of circulating anti-Xa activity after intravenous injection of standard heparin an of a low molecular weight heparin (CY-216) in normal and nephrectomized rabbits. Thromb Res 1985;40:129-133.
24. Palm M, Mattson C: Pharmacokinetics of heparin and low molecular weight heparin fragment (Fragmin) in rabbits with impaired renal or metabolic clearance. Thromb Haemost 1987;58:932-935.
25. Boneu B, Caranobe C, Cadroy Y, Dol F, Gabaig AM, Dupouy D, Sie P: Pharmacokinetic studies of standard unfractionated heparin, and low molecular weight heparins in the rabbit. Semin Thromb Hemost 1988;14:18-27.
26. Bara L, Billaud E, Gramond G, Kher A, Samama M: Comparative pharmacokinetics of a low molecular weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration. Thromb Res 1985; 39:631-636.
27. Nurmohamed MT, ten Cate JT, Stevens P, Hoek JA, Lins RL, ten Cate JW: Long-term efficacy and safety of a low molecular weight heparin in chronic hemodialysis patients: A comparison with standard heparin. ASAIO Trans 1991;37:M459-461.